HSJ Medicines Forum

14 October 2022 | Doubletree by Hilton, Tower of London



Establishing a new collaborative operating model to drive value and patient outcomes at a system level


Registration & Refreshments


Chair’s Opening Remarks

Dave West, Deputy Editor, HSJ



Building the future of integrated medicines: What does good look like?

The NHS and its industry partners face the biggest upheaval in medicines management and funding in a decade. In this opening keynote, we’ll be examining how the systemisation of the NHS will enable collaborative working and enable real benefits for population health, clinical quality and value, with a review of learnings from IPMO pilots. We’ll also review future decision-making structures at national, regional, ICS and place level, including clarification of the future role of RMOCs in order for systems.

David Webb, Chief Pharmaceutical Officer, NHS England and NHS Improvement


Panel Discussion

Working together across key stakeholders and systems to optimise access to innovative medicines

  • Identify and remove duplication and non-value adding processes which slow down innovative medicines reaching patients
  • Removing barriers to support faster implementation of national directives at a local level
  • Exploring the role of the ICS to enable better integrated working
  • Working with industry to bring medicines to the NHS at the right price

Claire Foreman, Director of Medicines Policy & Strategy, NHS England and NHS Improvement
Glenn Wells, Chief Partnerships Officer, MHRA
Paul Catchpole, Director, Value & Access Policy, ABPI
Meindert Boysen, Director, Centre for Health Technology Evaluation, NICE 


Panel Discussion

Establishing new responsibilities and shared accountability for Specialised Commissioning

  • Next steps for improving the delivery of care for rare diseases
  • How will the new funding system work for high-cost drugs and for allocating long-term funding?
  • What is going to change? Direction of travel, major challenges
  • Integrating specialised services with wider pathways of care
  • Reducing variation in the quality of services at a local level
  • Identifying and addressing skills and knowledge gaps
  • How to access the IMF?

Alison Tennant, Chief Pharmacist, Birmingham Women’s & Children’s NHS Foundation Trust
Mohammed Asghar, ICS Prescribing Governance Lead, Frimley Health & Care 
Inderjit Singh, Chief Pharmacist, University Hospitals Birmingham NHS Foundation Trust
Jatinder Harchowal, Chief Pharmacist, University College London Hospitals NHS Foundation Trust


Morning Refreshments & Networking


Interactive Discussion Groups: 
Join one of the following intimate and focused small-group discussions to share experiences with colleagues across the health system. Bringing together 12-15 participants, ensure you sign up early to secure your place at your preferred table. 

1. Realising the benefits of medicines optimisation initiatives across an ICS

- Identifying opportunities, challenges and then the solutions with meds op teams at CCG level, identifying MO initiatives across the ICS
- Delivering on Active Implementation and how to motivate and work with GPs / PCNs to ensure take up and roll out
- Improving patients outcomes and financial benefits to the NHS by improving care
- How to engage with other ICS stakeholders
- What population data resource the ICS would find valuable to support meds op initiatives
Moderator: Selma Abed, Head of Medicines Optimisation, Spirit Health

2. Taking a data driven approach to medicines optimisation

- How are you linking in health inequalities and medicines (prescribing and optimisation)? What data do you need?

- What are the challenges/pain points preventing you doing this at present? – budgets, ICS formations, IG constraints on data sharing etc

- Medicines Optimisation Strategy – how are you linking up ICS, Place and PCN? Learning from ideas and examples round the table?

- What does the future look like? What types of data should be brought in? What’s the aspiration and appetite? What do you want to see? What would help you?

Moderators: Meera Prakash, Clinical Facilitator & Rupinder Gill, Programme Manager - Medicines Optimisation, Optum

3. Translating population health into practice
Featuring: Vishal Mashru, Head PCN Medicines & Research, Cross Counties Healthcare PCN and North Blaby PCN
Moderator: Dave West, Deputy Editor, HSJ

Sponsored by Daiichi Sankyo UK 

4. Removing the barriers to access to medicines
- Understanding the barriers for patient access to new medicines
- What needs to be done to improve access and reduce inequalities?

Moderator: Jyotika Singh, Principal Consultant & Oliver Hudson, Content Director, Wilmington Healthcare


Networking Lunch


Panel Discussion

Driving value through an integrated approach to prescribing and medicines

  • Embedding medicines as the golden thread that runs through everything across the ICS to drive value for the patient, clinician and system
  • Approaching and measuring medicines value as a system – what system intelligence do you need?
  • Working together to make an impact in key priority areas:
    • Deprescribing and non-compliance
    • Patient safety, medication errors in prescribing
  • Exploring opportunities for a new collaboration and partnership with local authority
  • Integrated working to support medicines optimisation in patients with severe mental illness and learning disabilities 


Chetan Shah, Chief Pharmacist, Hertfordshire Partnership University NHS Foundation Trust
Ewan Maule, ICS Lead Pharmacist, North East & North Cumbria
Roger Fernandes, Chief Pharmacist & Clinical Director, Kings College Hospital NHS Foundation Trust



Exploring medicines budgeting and funding flows in the new ICS landscape

  • Collaborating and moving money around to focus on outcomes – shared experiences
  • Managing pooled budgets and potential for overspend
  • Redesigning medicines committees, their responsibilities and relationship with the ICB
  • Reviewing roles and budget management accountabilities: ICS vs Provider
  • What are the new funding routes, how are they being managed, how can they be accessed?

Henry Black, Chief Finance Officer, NHS North East London CCG


Panel Discussion

Designing an ICS medicines and prescribing workforce to enable collaboration and improved medicines use

  • Transitioning from multiple CCGs to one medicines team - standardising the offer and approach, meeting the specific requirements of the ICS
  • Enabling equalisation of resources to ensure safety and continuity of care
  • Working together as one team and developing collaborative relationships with acute providers and mental health trusts
  • Tackling recruitment and retention across the system
  • Supporting training and development of career pathways
  • Integrating community pharmacy and PCN pharmacists and pharmacy technicians into the ICS team
  • What role would (non-NHS) providers play in the delivery of medicines and integration of medicines?


Mildred Johnson, Clinical Director of Pharmacy & Medicines Optimisation, Maidstone & Tunbridge Wells NHS Trust & Chair, Kent, Surrey & Sussex Chief Pharmacists & Medicines Management Leads Network 
Vanessa Burgess, Chief Pharmacist, South East London CCG
Mandeep Butt, Director, Integrated Pharmacy & Medicines  Optimisation Programme, North Central London STP


Afternoon Refreshments & Networking


Panel Discussion

Digitising medicines management to enable an integrated and patient-centred approach

  • Establishing a one-patient view across systems
  • The power of connected data for improved communication, safety and continuity of care
  • Establishing interoperability of systems
  • E-prescribing
  • Transforming lives with digital medicines: What lies ahead?


Will Willson, Director of Pharmacy, East Kent Hospital University Foundation Trust
Julian Wyatt, Project Lead, Lancashire & South Cumbria ICS
Liz Butterfield, Pharmacy Advisor, Kent Surrey Sussex Academic Health Science Network


Panel Discussion

Addressing health inequalities through effective prescribing

  • What does population health management mean and how does it relate to pharmacy and medicines?
  • Understanding how to utilise data and analytics to identify opportunities to drive better health outcomes
  • Evaluating key national public health priorities - and how a Population Health approach could drive positive change
  • Identifying opportunities to intervene earlier with medicines
  • Changing approaches to investment and value
  • Optimising the role of community pharmacy to improve Population Health


Yousaf Ahmad, Chief Pharmacist & Director of Medicines Optimisation, NHS Frimley Health & Social Care
Raliat Onatade, Chief Pharmacist and Director of Medicines and Pharmacy, North East London CCG/ICS & Group Chief Pharmacist and Clinical Director for Medicines Optimisation, Barts Health NHS Trust 
Helen Kilminster, Senior Clinical Pharmacist, Tower Hill Medical Practice & Vice President, Primary Care Pharmacy Association 


Chair’s Closing Remarks

Dave West, Deputy Editor, HSJ